Palisade Bio jumps following Oppenheimer outperform initiation
Seeking Alpha ·
Oppenheimer has initiated Palisade Bio ( PALI ) at outperforming, sending the stock ~14% higher in Thursday morning trading. The investment bank has an $8 price target (321% upside based on July 22 close). Analyst Lelend Gershell sees strong potential in PALI-2108, which
DYAX Investor Sentiment
Bullish (Long) 47% · Bearish (Short) 53%
483 participants
Related News
- Indra Sistemas, S.A. reports 1H results
- Origin Bancorp anticipates high single-digit net interest income growth as it targets at least 1.15% ROA in Q4
- United Rentals outlines 2026 revenue of $17.5B-$17.8B while raising adjusted EBITDA view to $7.975B-$8.125B
- Dyne a new overweight at Cantor on platform for neuromuscular disorders
- WTI crude will near $115/bbl by the end of 2026 – Kalshi
- Top Midday Stories: Alphabet Doubles Q2 Capital Spending; Tesla Reports Earnings Decline, Negative Free Cash Flow
